PF-Atlas › Clinical Trials › NCT03287414

Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis

VAY736 · Phase 2

Registry ID

NCT03287414

Phase

Phase 2

Status

Terminated

Drug / intervention

VAY736

Sponsor

Novartis Pharmaceuticals

Start

2017-12-20

About this trial

VAY736 is evaluated in NCT03287414, a Phase 2 idiopathic pulmonary fibrosis study sponsored by Novartis Pharmaceuticals. Current status: Terminated.

View NCT03287414 on ClinicalTrials.gov →

Explore related

All VAY736 trials All IPF trials

Medical disclaimer. This page summarizes public trial data for NCT03287414 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.